

Name • Enzymicals AG

Address/P.O. Box • Walther-Rathenau-Straße 49a

Postal Code/City • 17489 Greifswald

Country • Germany

Contact Person • Dr Ute Liebelt

Telephone • +49-3834-515470

Fax • +49-3834-515473

Email Address • info@enzymicals.com

Internet Website • www.enzymicals.com

Number of Employees • 17

Founded (year) • 2009

Type of Laboratory • | Chemistry

| Genetic engineering

| S1 Biotech lab

| access to S2 Biotech lab

Areas of Activity • | Development and production of enzymes

| Tailor-made fine chemicals, intermediates, and APIs

| Customer-specific solutions in enzyme technology, biotransformation, process development, and piloting

Biological Patents • IP protected by international patent applications and granted patents

External • | BBG Braun Beteiligungs GmbH

Collaborations | BRAIN AG

| Herbrand PharmaChemicals GmbH

| National and international enterprises of fine chemical and pharmaceutical industry

| Broad international academic R&D collaboration

Enzymicals

Enzymes | Chemicals | Solutions


Enzymicals AG is your experienced partner for biocatalytic synthesis. An interdisciplinary team of 17 scientists and technicians is currently engaged in providing integrated solutions for industrial biocatalysis. The focus of the independent SME is the development and production of enzymes, the chemo-biocatalytic synthesis of fine and specialty chemicals, as well as the development, scale up, and piloting of robust chemo-biocatalytic processes. These core areas are combined to realise tailor-made solutions for custom development and manufacturing. Our continuous activities in academic partnering and industrial collaborations result in the delivery of state-of-the-art concepts which are applicable at commercial scale.

Products & services

Tailor-made enzymes, customised chemicals, and individual process solutions

Enzymicals is an outstanding resource of enzymes suitable for diagnostics, research, and development, as well as for commercial production. Our enzyme portfolio contains a continually expanding biocatalytic toolbox, with innovative biocatalysts from the class of e.g. transaminases, monooxygenases, halohydrin dehalogenases, imine reductases, and hydrolases at desired quality grades to meet customer-specific demands with top performance. Selected products are incorporated in our online catalogue.

We deliver concept-to-completion comprehensive solutions to create high-performance protein-based products and processes. For this, we discover and produce enzymes based on the demands of our customers and partners. Our technology platform covers the identification of suitable catalysts from strain or enzyme collections, databases, or metagenome libraries, as well their functional expression in a range of microbial host systems. Additionally we offer tailor-made protein expression and optimisation service. In this way, almost any biocatalyst of interest can be supplied to analytical and commercial scale. A catalyst suitable for the pro-



www.enzymicals.com

duction of your target compound can be optimised via our protein engineering technology to provide the best performance available.

Dedicated to designing, developing and implementing innovative cost-effective and scalable chemo-biocatalytic routes to fine chemicals & APIs, Enzymicals offers recognised expertise in the use of enzymatic processes for complex chemical synthesis. We develop scalable strategies for the synthesis of your desired compound, which include feasibility studies as well as the process development and its piloting. For this we are able to combine efficient enzymatic and chemical synthesis steps.

Together with our network partners, we expand our service to ASMF filing, regulatory affairs, cGMP production, and bulk scale supply. The combination of best catalysts with optimised chemistry and the integration of processing aspects enabled us to increase the speed of delivery of effective solutions and expand our business along the whole value chain of the white biotechnology industry.

Management

Dr Ulf Menyes (CEO)